Superficial Cervical Plexus Block for Orthognathic Surgery
Maxillofacial Injuries, Maxillofacial Trauma, Maxillofacial Abnormalities
About this trial
This is an interventional treatment trial for Maxillofacial Injuries focused on measuring Orthognathic surgery, Postoperative pain management, Superficial cervical plexus block
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) classification I-II
- Scheduled for orthognathic surgery under general anesthesia
Exclusion Criteria:
- history of bleeding diathesis,
- receiving anticoagulant treatment,
- known local anesthetics and opioid allergy,
- infection of the skin at the site of the needle puncture,
- pregnancy or lactation,
- patients who do not accept the procedure
Sites / Locations
- Istanbul Medipol University Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Group S = SCPB group
Group C = Control group
US-guided SCPB will be performed at the end of the surgery before extubation, with patients in the supine position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the high frequency linear probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath and a 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. Sternocleidomastoid (SCM) muscle will be visualized. The 22 G needle will be inserted between the SCM and the prevertebral fascia by using in plane technique horizontally. The needle tip will be corrected with injecting 2 ml of normal saline. Then a 20 mL dose of 0.25% bupivacaine will be injected here. The same procedure will be performed for the opposite site (totally 40 mL dose of 0.25% bupivacaine).
Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.